Analytical Data
-
基因名
HLA-A*11:01&B2M&KRAS G12D(VVVGADGVGK)
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGADGVGK
-
分子量
51-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the recombinant protein HLA-A*11:01 in conjunction with β2-microglobulin (B2M) and the KRAS G12D mutation (amino acid sequence VVVGADGVGK) is rooted in the quest to enhance cancer immunotherapy. HLA-A*11:01 is a major histocompatibility complex (MHC) class I molecule that plays a crucial role in presenting tumor-derived peptides to CD8+ T cells, thus triggering an immune response. The KRAS G12D mutation is prevalent in various cancers, especially pancreatic and colorectal cancers, and is associated with poor patient prognosis. By engineering the HLA-A*11:01 molecule to present the specific KRAS G12D-derived peptide, researchers aim to elicit a robust and targeted cytotoxic T cell response against cancer cells expressing this mutation. This approach could potentially lead to novel therapeutic strategies, including peptide-based vaccines or adoptive T cell therapies, aimed at improving the immune system’s ability to recognize and eliminate KRAS-driven tumors. Understanding the interactions between HLA-A*11:01, B2M, and the KRAS G12D peptide is critical for optimizing the design of anticancer immunotherapies and could pave the way for personalized treatment options tailored to individual patient profiles. The development of this recombinant protein serves as a vital step in harnessing the immune system to fight against tumors characterized by specific genetic alterations, thus contributing to the advancement of precision medicine in oncology.
